Biomarker & Intervention Discovery
Peripheral Neuropathy (Diabetic Peripheral Neuropathy)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
NIH funding$194MFY2025 · RCDC estimate
Spontaneous remissionProgressive with worsening glycaemic control; reversal essentially not possible with current treatments once…
Best-intervention remissionIntensive glycaemic control in T1DM (DCCT): 60% reduction in neuropathy development; pain management (duloxetine…
Gap sizeVery large — no disease-modifying therapy approved; pain treatment is the only intervention most patients receive
Primary barrierbiological (pain modification) + practice (prevention gap)
Full remission profile →
Remission & chronicity
Spontaneous remission
Progressive with worsening glycaemic control; reversal essentially not possible with current treatments once established; spontaneous improvement only in cases of rapid glycaemic normalisation early in course
Best-intervention remission
Intensive glycaemic control in T1DM (DCCT): 60% reduction in neuropathy development; pain management (duloxetine, pregabalin): 30-50% pain reduction but no disease modification; alpha-lipoic acid IV: nerve conduction velocity improvement at 3 weeks (SYDNEY 2 trial); SGLT2 inhibitors: emerging data on neuropathy protection
Gap size
Very large — no disease-modifying therapy approved; pain treatment is the only intervention most patients receive
Primary barrier
biological (pain modification) + practice (prevention gap)
Prevention through glycaemic control is highly effective but prevention means tight glycaemic control for decades; pain treatment gives symptomatic relief only; opioid prescribing for DPN pain remains common despite guidelines against it; few patients are offered alpha-lipoic acid which has the strongest disease-modification signal
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Peripheral Neuropathy (Diabetic Peripheral Neuropathy)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."